Scaling approaches for the prediction of human clearance of LNA-i-mir-221: A retrospective validation
LNA-i-miR-221 is a novel microRNA(miRNA)-221 inhibitor designed for the treatment of human malignancies. It has recently undergone phase 1 clinical trial (P1CT) and early pharmacokinetics (PKs) data in cancer patients are now available. We previously used multiple allometric interspecies scaling met...
Saved in:
| Main Authors: | Massimiliano Fonsi, Jacques Fulbert, Pierre-Andre Billat, Mariamena Arbitrio, Pierosandro Tagliaferri, Pierfrancesco Tassone, Maria Teresa Di Martino |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Current Research in Pharmacology and Drug Discovery |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590257124000245 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Locked nucleic acid-modified antisense oligonucleotides attenuate scar hyperplasia through targeted inhibition of CTGF
by: Jinhe Li, et al.
Published: (2025-08-01) -
Involvement of lncRNA in cancer diagnosis and prognosis and clinical implications
by: Chainsee Saini, et al.
Published: (2025-01-01) -
Non-coding RNAs: emerging biomarkers and therapeutic targets in cancer and inflammatory diseases
by: Basma Hossam Abdelmonem, et al.
Published: (2025-03-01) -
Extracellular vesicles as novel therapeutic targets and diagnosis markers
by: Yu Zhang, et al.
Published: (2022-12-01) -
The RNA revolution in medicine: from gene regulation to clinical therapeutics
by: Jiwon Jeong, et al.
Published: (2025-12-01)